ReP USP - Resultado da busca

Filtros : "Allain, Thibault" "MUSCARA, MARCELO NICOLAS" "ICB" Removidos: "IFSC111" "Gama, Patrícia" "Porto Rico" Limpar

Filtros

Autores USP
- muscara, marcelo nicolas (~2)
- costa, soraia kátia pereira (~1)
- dallazen, jorge luiz (~1)
Ano de publicação
- 2020 (~2)
Assuntos
- analgésicos (2)
- farmacologia (2)
- medicamento (2)
- sistema gastrointestinal (2)
- anti-inflamatórios (1)

Artigo de periodico
A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug (2020)
Wallace, John L. ; Nagy, Peter ; Feener, Troy D.; Allain, Thibault ; Ditrói, Tamás; Vaughan, David J.; Muscará, Marcelo Nicolás (Orientador) ; De Nucci, Gilberto ; Buret, Andre G.
Fonte: British Journal of Pharmacology. Unidade: ICB
Assuntos: FARMACOLOGIA, ENSAIO CLÍNICO, ANTI-INFLAMATÓRIOS, SISTEMA GASTROINTESTINAL, MEDICAMENTO, ANALGÉSICOS, FÁRMACOS GASTRINTESTINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WALLACE, John L. et al. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, n. 4, p. 769-777, 2020Tradução . . Disponível em: https://doi.org/10.1111/bph.14641. Acesso em: 13 jun. 2024.
APA
Wallace, J. L., Nagy, P., Feener, T. D., Allain, T., Ditrói, T., Vaughan, D. J., et al. (2020). A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, ( 4), 769-777. doi:10.1111/bph.14641
NLM
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1111/bph.14641
Vancouver
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 jun. 13 ] Available from: https://doi.org/10.1111/bph.14641
Artigo de periodico
Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids (2020)
Costa, Soraia Katia Pereira ; Muscará, Marcelo Nicolás (Orientador) ; Allain, Thibault ; Dallazen, Jorge Luiz ; Santos, Larissa Gonzaga ; Buret, Andre G.; Vaughan, David J.; Fowler, Christopher J.; De Nucci, Gilberto ; Wallace, John L.
Fonte: Antioxidants & Redox Signaling. Unidade: ICB
Assuntos: FARMACOLOGIA, ANALGÉSICOS, INFLAMAÇÃO, DOR, ÚLCERA GÁSTRICA, SISTEMA GASTROINTESTINAL, ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Soraia Katia Pereira et al. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, p. 7 , 2020Tradução . . Disponível em: https://doi.org/10.1089/ars.2019.7884. Acesso em: 13 jun. 2024.
APA
Costa, S. K. P., Allain, T., Dallazen, J. L., Santos, L. G., Buret, A. G., Vaughan, D. J., et al. (2020). Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, 7 . doi:10.1089/ars.2019.7884
NLM
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 jun. 13 ] Available from: https://doi.org/10.1089/ars.2019.7884
Vancouver
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 jun. 13 ] Available from: https://doi.org/10.1089/ars.2019.7884

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo 2012 - 2024